One of the keys to cutting the cost of drugs in the United States is to raise their cost in other countries, Eli Lilly CEO ...

Two Saudi Arabian agencies signed on with Vertex Pharmaceuticals to help boost the countr | The Vertex agreement is part of ...

Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...

In tandem with Enhertu’s inclusion in China’s national insurance program, Daiichi Sankyo is planting a foothold in local ...

After recently taking steps to undo messaging about a rival product in the European Union, CSL Vifor is carrying its amends ...

With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a ...

With a positive phase 3 trial in chronic lymphocytic leukemia (CLL), Eli Lilly hopes to convert Jaypirca’s unique accelerated ...

With EuroAPI’s restructuring plan underway, the Sanofi spinoff has pulled a new CEO from within its ranks to guide the ...

Apparently, it takes three to bring Boehringer Ingelheim and Eli Lilly’s joint “It Takes 2” initiative to the annual ...

In a 60 million euro ($63 million) expansion project, BioMarin is adding a new four-story laboratory to its Shanbally ...

Roche’s Lunsumio may be the first CD20xCD3 T-cell engager approved by the FDA, but intravenous administration puts the drug ...

Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...